BiondVax Pharmaceuticals Ltd.

BVXVNASDAQHealthcare

$1.36

+$0.01(+0.74%)

Market Cap$4966625

P/E Ratio—

52W High$11.49

52W Low$0.63

Avg Volume38K

Open$1.32

Beta2.37

Overview

BiondVax Pharmaceuticals Ltd. (BVXV) Revenue

Annual & quarterly revenue history · segment & region breakdown

BVXV · revenue · updated Jun 9, 2026

Core revenue metrics

Trailing 12 months

BiondVax Pharmaceuticals Ltd. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY —

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

33 employees

—

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · BiondVax Pharmaceuticals Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

– · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth

BVXV revenue by year · BVXV revenue history · BVXV annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income BiondVax Pharmaceuticals Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

BiondVax Pharmaceuticals Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from BiondVax Pharmaceuticals Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

BVXV revenue · 4 questions

BVXV's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

BVXV revenueBVXV annual revenuewhat is BVXV revenueBVXV TTM revenue

▸ Source: FMP · BiondVax Pharmaceuticals Ltd. SEC filings · GAAP · BiondVax Pharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026